Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate 6-Month Formulation Study
NCT03345342Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- May 2020
- Modality
- Metabolically Activated Prodrugs
- Countries
- 21
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Started Nov 2017; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03345342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345342.